Creating Novel Antibodies with Purpose and Precision
Our Dynamic Precision Library platform is composed of three proprietary technologies tailored to three key attributes of antibody-based therapeutic modalities:
- NEObody™ enables the generation of antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOAs, which we refer to as NEObodies.
- SAFEbody™ enables the generation of masked antibodies and NEObodies that are designed to be selectively activated in the tumor microenvironment, or TME, potentially limiting on-target off-tumor toxicity in normal tissues, which we refer to as SAFEbodies.
- POWERbody™ applies our SAFEbody technology to powerful antibody-based modalities such as creating new SAFE bispecific T-cell engagers, SAFE antibody-drug conjugates, or SAFE ADCs, or antibodies that are designed to reach beyond the therapeutic potency of traditional monospecific antibodies.
“The successful discovery of therapeutic antibodies hinges on identifying appropriate affinity binders targeting a diversity of molecular epitopes… Antibody campaigns that yield such broad “epitope coverage” increase the likelihood of identifying candidates with the desired biological functions.” 1
1 Sivasubramanian A, Estep P, Lynaugh H, et al. Broad epitope coverage of a human in vitro antibody library. MAbs. 2017;9(1):29-42. doi:10.1080/19420862.2016.1246096 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240653/ Accessed August 20, 2020